Figures & data
Table 1 Demographics/characteristics of MONARCH sarilumab and adalimumab patient populations (base case analysis) and MOBILITY aggregate patient population (individual patient simulation)
Table 2 Treatment response rates applied to short-term and long-term models
Figure 1 Model structure for long-term analysis.
![Figure 1 Model structure for long-term analysis.](/cms/asset/b58cef62-0460-4ba0-8594-a8409ddb6a5c/dceo_a_183076_f0001_c.jpg)
Table 3 Drug costs
Figure 2 Responders (%) and NNT.
![Figure 2 Responders (%) and NNT.](/cms/asset/abb1af8d-9a97-4654-825e-ceea7545c57d/dceo_a_183076_f0002_c.jpg)
Figure 3 Cost per responder at 24 weeks: (A) base case analysis and (B) sensitivity analyses.
![Figure 3 Cost per responder at 24 weeks: (A) base case analysis and (B) sensitivity analyses.](/cms/asset/d3a6399f-8a62-4837-bb5a-f775055389eb/dceo_a_183076_f0003_c.jpg)
Figure 4 Long-term incremental analyses.
![Figure 4 Long-term incremental analyses.](/cms/asset/3352ec65-44e1-4c69-8df5-928e0d3e7730/dceo_a_183076_f0004_c.jpg)
Table 4 Long-term analyses: costs
Table 5 Long-term analyses: outcomes